Financial Performance - Arcus reported revenues of 36millionforQ42024,upfrom31 million in Q4 2023, with 28millionfromlicenseanddevelopmentservicerevenuesrelatedtoGileadcollaboration[13].−TotalrevenuesforQ42024were36 million, a 16% increase from 31millioninQ42023[24].−Licenseanddevelopmentservicerevenueincreasedto28 million in Q4 2024, up from 22millioninQ42023,representinga2794 million, compared to a net loss of 81millioninQ42023,indicatinga161.03 for Q4 2024, compared to 1.08 for Q4 2023[24]. Research and Development - Research and Development (R&D) expenses increased to 111 million in Q4 2024 from 93 million in Q4 2023, driven by higher costs in early-stage R&D and increased headcount[13]. - Research and development expenses rose to 111 million in Q4 2024, compared to 93millioninQ42023,reflectinga19992 million, an increase from 866millionattheendof2023,primarilyduetoa320 million cash infusion from Gilead[13]. - Cash, cash equivalents, and marketable securities totaled 992millionasofDecember31,2024,upfrom866 million a year earlier, representing a 15% increase[26]. - Total assets increased to 1,150millionin2024from1,095 million in 2023, a growth of 5%[26]. - Total liabilities rose to 665millionin2024,comparedto633 million in 2023, marking a 5% increase[26]. - Total stockholders' equity increased to 485millionin2024from462 million in 2023, a 5% growth[26]. - The company expects its cash and investments to be sufficient to fund operations through initial pivotal readouts for its investigational products[19]. General and Administrative Expenses - General and Administrative (G&A) expenses were 28millioninQ42024,slightlydownfrom29 million in Q4 2023[13].
Arcus Biosciences(RCUS)2025-02-25 21:07